130596-62-2

Usage

Uses

Used in Pharmaceutical Industry:
4,4-dimethyl-1,4-azasilinane hydrochloride is used as a reagent for the synthesis of various organic compounds and pharmaceutical drugs, contributing to the development of new drug molecules.
Used in Cancer Treatment:
In the field of oncology, 4,4-dimethyl-1,4-azasilinane hydrochloride is used as a potential therapeutic agent for the treatment of various types of cancer, leveraging its ability to target and treat cancer cells.
Used in Neurological Disorders Treatment:
4,4-dimethyl-1,4-azasilinane hydrochloride is utilized as a potential therapeutic agent in the treatment of neurological disorders, owing to its potential to address specific conditions within this medical field.
Used in Antimicrobial Agents Development:
In the area of infectious diseases, 4,4-dimethyl-1,4-azasilinane hydrochloride is used as a compound with potential antimicrobial properties, making it a candidate for the development of new antimicrobial agents to combat resistant pathogens.

Upstream product

• 130596-61-1 1-benzyl-4,4-dimethyl-[1,4]azasilinane hydrochloride 
• 130596-60-0 1-benzyl-4,4-dimethyl-1,4-azasilinane 
• 10519-87-6 divinyldimethylsilane 
• 51664-50-7 dimethylbis(2-bromoethyl)silane 

Downstream Products

• 1430321-42-8 1-(2-fluoro-4-nitrophenyl)-4,4-dimethyl-1,4-azasilinane 
• 1430321-66-6 1-(2,6-difluoro-4-nitrophenyl)-4,4-dimethyl-1,4-azasilinane 
• 1430321-43-9 benzyl 4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluorophenylcarbamate 
• 1430321-67-7 benzyl (4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3,5-difluorophenyl)carbamate 
• 1430321-44-0 (S)-5-(aminoniethyl)-3-(4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)oxazolidin-2-one 
• 1430321-53-1 (S)-5-(aminomethyl)-3-(4-(4,4-diniethyl-1,4-azasilinan-1-yl)-3,5-difluorophenyl)oxazolidin-2-one 
• 1430321-50-8 (R)-(3-(4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl methanesulfonate 
• 1430321-45-1 (S)-N-((3-(4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 1430321-46-2 (S)-N-((3-(4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)propionamide 
• 1430321-54-2 (S)-N-((3-(4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3,5-difluorophneyl)-2-oxooxazolidin-5-yl)methyl)acetamide 
• 1430321-55-3 (S)-N-((3-(4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3,5-difluorophenyl)-2-oxooxazolidin-5-yl)methyl)propionamide 
• 1430321-47-3 (S)-methyl ((3-(4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)-2-oxooxazolidin-5-yl) methyl)carbamate 
• 1430321-56-4 (S)-methyl (3-(4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3,5-difluorophenyl)-2-oxooxazolidin-5-yl)methylcarbamate 
• 1430321-48-4 (S)-O-methyl ((3-(4-(4,4-dimethyl-1,4-azasilinan-1-yl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)carbamothioate 

Relevant academic research and scientific papers

Substituted benzimidazole derivatives

The invention belongs to the field of pharmaceutical chemistry, particularly relates to substituted benzimidazole derivatives as well as a preparation method and pharmaceutical composition thereof and further relates to an application of the substituted b

Design, Synthesis, and Identification of Silicon Incorporated Oxazolidinone Antibiotics with Improved Brain Exposure

Therapeutic options for brain infections caused by pathogens with a reduced sensitivity to drugs are limited. Recent reports on the potential use of linezolid in treating brain infections prompted us to design novel compounds around this scaffold. Herein, we describe the design and synthesis of various oxazolidinone antibiotics with the incorporation of silicon. Our findings in preclinical species suggest that silicon incorporation is highly useful in improving brain exposures. Interestingly, three compounds from this series demonstrated up to a 30-fold higher brain/plasma ratio when compared to linezolid thereby indicating their therapeutic potential in brain associated disorders.

SILA ANALOGS OF OXAZOLIDINONE DERIVATIVES AND SYNTHESIS THEREOF

The invention discloses silaanalogs of oxazolidinone compounds, to pharmaceutical compositions and to the synthesis of the oxazolidinone derivatives of formula I. The invention further relates to methods of treating a subject suffering with gram positive pathogens including those resistant to methicillin and vancomycin using the compound(s) or modulation of coagulation properties of blood-clotting cascade or compositions of the oxazolidinone derivatives of the invention.

SILA ANALOGS OF OXAZOLIDINONE DERIVATIVES AND SYNTHESIS THEREOF

The invention discloses silaanalogs of oxazolidinone compounds, to pharmaceutical compositions and to the synthesis of the oxazolidinone derivatives of formula I. The invention further relates to methods of treating a subject suffering with gram positive pathogens including those resistant to methicillin and vancomycin using the compound(s) or modulation of coagulation properties of blood-clotting cascade or compositions of the oxazolidinone derivatives of the invention.

NOVEL TRIAZOLOPYRIMIDINE DERIVATIVES

The present invention relates to novel triazolopyrimidine derivatives of formula (I) as active ingredients which have microbiocidal activity, in particular fungicidal activity: wherein the substituents are as defined in claim 1.